IQVIA™ Real-World Insights Bibliography

Liver transplant associated with paracetamol overdose: results from the seven-country SALT study
Author(s): Sinem Ezgi Gulmez,1 Dominique Larrey,2 Georges- Philippe Pageaux,2 Jacques Bernuau,3 Franco Bissoli,4 Yves Horsmans,5 Douglas Thorburn,6 P. Aiden McCormick,7 Bruno Stricker,8 Massoud Toussi,9 Séverine Lignot-Maleyran,1 Sophie Micon,1 Fatima Hamoud,1 Régis Lassalle,1 Jérémy Jové,1 Patrick Blin1 & Nicholas Moore1
Affiliations(s): 1CIC Bordeaux CIC1401 Pharmaco-épidémiologie, Université de Bordeaux, F-33076 Bordeaux, France, 2CHU St Eloi Hospital, Liver Unit, Montpellier, France, 3Beaujon Hospital, Liver Unit, Clichy, France, 4Department of Internal Medicine, Clinica San Gaudenzio, Novara, Italy, 5Department of Gastroenterology, Louvain Catholic University, Louvain, Belgium, 6Liver Unit, Royal Free NHS Trust, London, UK, 7Liver Unit, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland, 8Department of Epidemiology, Erasmus University, Rotterdam, Netherlands and 9IMSHealth, Real World Evidence Solutions, France
Publication(s):  British Journal of Clinical Pharmacology 2015
Document Type(s): Article,
Countries: France, Greece, Ireland, Italy, Netherlands, Portugal, UK,
C:
Y:
Drug safety, Public Health,
2015
  L:
A:
English
Epidemiological study,
  Add to report
 
 
Survey on appropriateness of use of nimesulide in nine European countries
Author(s): Franchi S1, Heiman F2, Visentin E2, Sacerdote P1.
Affiliations(s): 1Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. 2Cegedim Strategic Data Medical Research Srl, Milan, Italy.
Publication(s):  Drug, Healthcare and Patient Safety 2015:7 51-55
Document Type(s): Article,
Countries: Bulgaria, Czech, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia,
C:
Y:
Pain,
2015
  L:
A:
English
Survey research,
  Add to report
 
 
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
Author(s): Emery P1, Gottenberg JE2, Rubbert-Roth A3, Sarzi-Puttini P4, Choquette D5, Taboada VM6, Barile-Fabris L7, Moots RJ8, Ostor A9, Andrianakos A10, Gemmen E11, Mpofu C12, Chung C13, Gylvin LH12, Finckh A14.
Affiliations(s): 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 2Department of Rheumatology, CHU Strasbourg, Strasbourg, France. 3University of Cologne, Cologne, Germany. 4L Sacco University Hospital, Milan, Italy. 5University of Montreal, Montreal, Canada. 6Facultad de Medicina, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain. 7Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, Mexico. 8Department of Rheumatology, University of Liverpool, Liverpool, UK. 9Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 10Hellenic Foundation for Rheumatological Research, Athens, Greece. 11Quintiles, Rockville, Maryland, USA. 12F Hoffmann-La Roche Ltd, Basel, Switzerland. 13Genentech Inc, San Francisco, California, USA. 14University Hospital of Geneva, Geneva, Switzerland.
Publication(s):  Ann Rheum Dis. 2015 Jun;74(6):979-84
Document Type(s): Article,
Countries: Canada, Colombia, France, Germany, Greece, Italy, Mexico, Norway, Portugal, Spain, UK,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Rheumatology,
2015
  L:
A:
English
Clinical setting: hospital, clinical setting: Secondary care, Prospective study, RWLPR (Real-World Late Phase Research-quintiles,
  Add to report
 
 
Quantification of switching trends in the Greek pharmaceutical market during the period of crisis
Author(s): Ollandezos M1, Charitonidis S2, Papadopoulos K1, Katsoulakis M2, Kofinas K2, Kyriopoulos J3
Affiliations(s): 1Pan Hellenic Union of Pharmaceutical Industry, Athens, Greece, 2IMS Health Hellas, Athens, Greece, 3National School of Public Health, Athens, Greece
Publication(s):  ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands
Document Type(s): Poster,
Countries: Greece,
C:
Y:
Health policy,
2014
  L:
A:
English
Methodology,
  Add to report
 
 
Generic penetration within top-10 genericized molecules ? Greece versus major European countries
Author(s): Charitonidis S1, Kofinas K1, Katsoulakis M1, Papadopoulos K2, Ollandezos M2, Kyriopoulos J3
Affiliations(s): 1IMS Health Hellas, Athens, Greece, 2Pan Hellenic Union of Pharmaceutical Industry, Athens, Greece, 3National School of Public Health, Athens, Greece
Publication(s):  ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands
Document Type(s): Poster,
Countries: Greece,
C:
Y:
Health policy,
2014
  L:
A:
English
Pricing & Reimbursement,
  Add to report
 
 
Primary prevention of cardiovascular disease in Greece: Greek results of the EURIKA study.
Author(s): Moses Elisaf1, Emmanouil Tzouvelekis2, Nikos Nikas2; on behalf of the Greek EURIKA Investigators
Affiliations(s): 1 Department of Internal Medicine, University Hospital of Ioannina, Ioannina, 2 Medical Department, AstraZeneca SA, Athens, Greece
Publication(s):  Hellenic J Cardiol. 2014 May-Jun;55(3):217-26
Document Type(s): Article,
Countries: Greece,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2014
  L:
A:
English
Survey research,
  Add to report
 
 
Economic evaluation of Rivaroxaban in stroke prevention among patients with Atrial Fibrillation in Greece
Author(s): Kourlaba G1, Maniadakis N1, Andrikopoulos G2, Vardas P3, Llyod A4, Asukai Y4, Evers T5
Affiliations(s): 1National School of Public Health, Athens, Greece, 2Henry Dunant Hospital, Athens, Greece, 3University of Crete, Heraklion, Crete , Greece, 4IMS Health, London, UK, 5Bayer Schering Pharma AG, Wuppertal, Germany
Publication(s):  ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany
Document Type(s): Poster,
Countries: Greece,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2012
  L:
A:
English
Economic evaluation,
  Add to report
 
 
Economic evaluation of Rivaroxaban in the treatment of Deep Vein Thrombosis in Greece
Author(s): Kourlaba G1, Maniadakis N1, Giannoukas A2, Katsamouris A3, Katsenis K4, Lazarides M5, Matsagas M6, Lowin J7, McLeod EJ8, Bamber L9
Affiliations(s): 1National School of Public Health, Athens, Greece, 2University of Thessaly, Larissa, Greece, 3University of Crete, Heraklion, Crete, Greece, 4University of Athens, Athens, Greece, 5Democritus University, Thrace, Greece, 6University of Ioannina, Ioannina, Greece, 7IMS Health, London , UK, 8IMS Health, London, UK, 9Bayer Pharma AG, Wuppertal, Germany
Publication(s):  ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany
Document Type(s): Poster,
Countries: Greece,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2012
  L:
A:
English
Economic evaluation,
  Add to report
 
 
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.
Author(s): Jose´ R. Banegas 1,2*, Esther Lo´pez-Garcı´a 1,2, Jean Dallongeville3, Eliseo Guallar 4,5,6,7, Julian P. Halcox8, Claudio Borghi 9, Elvira L. Masso´-Gonza´lez 10, Francisco J. Jime´nez 11, Joep Perk12, Philippe Gabriel Steg13, Guy De Backer 14,and Fernando Rodrı´guez-Artalejo1,2
Affiliations(s): 1 Department of Preventive Medicine and Public Health, School of Medicine, Universidad Auto´noma de Madrid/IdiPAZ, Avda Arzobispo Morcillo, 2, 28029 Madrid, Spain; 2 CIBER of Epidemiology and Public Health, Madrid, Spain; 3 Inserm U 744, Institut Pasteur de Lille, 59019 Lille Cedex, France; 4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 5 Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 6 Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 7 Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Research (CNIC), Madrid 28029, Spain; 8 Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; 9 Department of Internal Medicine, Aging and Clinical Nephrology, University of Bologna, Bologna, Italy; 10Medical Department, AstraZeneca Farmace´utica Spain, S.A., 28003 Madrid, Spain; 11Medical Department, AstraZeneca Europe, 1935 Zaventem, Belgium; 12School of Health and Caring Sciences, Linnaeus University, 391 82 Kalmar, Sweden; 13INSERM U 698, Assistance Publique–Hoˆpitaux de Paris and Universite´ Paris-Diderot, Paris, France; and 14Department of Public Health, University of Gent, 9000 Gent, Belgium
Publication(s):  Eur Heart J. 2011 Sep;32(17):2143-52
Document Type(s): Article,
Countries: Austria, Belgium, France, Germany, Greece, Norway, Spain, Sweden, Switzerland, Turkey, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2011
  L:
A:
English
Observational study, Prospective study,
  Add to report
 
 
Country differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in Europe.
Author(s): Papageorgiou G1, Cañas F, Zink M, Rossi A.
Affiliations(s): 1Department of Psychiatry, Evangelismos General Hospital
Publication(s):  Eur Psychiatry. 2011 Mar;26(1 Suppl 1):17-28. doi: 10.1016/S0924-9338(11)71710-2.
Document Type(s): Article,
Countries: Germany, Greece, Italy, Spain,
Click here for the abstract
C:
Y:
Neurological disorders,
2011
  L:
A:
English
Survey research,
  Add to report
 
 
First Page Previous Page  2 of 3 Next Page Last Page